FDA Launches New ALS Clinical Trial Readiness Project

The project uses wearable sensors to track patient gait, potentially improving how future drug treatments are evaluated.

Updated on Oct. 30, 2026 in Stroke

A close-up of a wearable motion sensor strapped to an ankle in a clinical setting. — The FDA has launched a clinical trial readiness project at Massachusetts General Hospital to validate wearable digital sensors for measuring ALS patient gait. AI Illustration. Upload story photo >

Live Poll

Do you believe using digital wearable sensors in medical trials will improve patient health outcomes?

The FDA has launched a clinical trial readiness project at Massachusetts General Hospital to validate the use of digital sensors for measuring gait velocity in ALS patients. This initiative aims to determine if wearable data can serve as reliable outcome measures in future drug studies.

Why it matters

Currently, ALS trials rely on traditional measures that may not capture subtle changes in patient mobility. This research seeks to standardize digital data collection, potentially streamlining the evaluation of new treatments for adults living with ALS.

The clinical trial readiness project evaluates the 95th centile of stride velocity measured via wearable sensors. It aims to establish how this digital marker correlates with traditional ALS outcome measures and patient-reported usability.

The players

FDA

The federal agency responsible for regulating medical products and overseeing clinical trial standards.

Massachusetts General Hospital

A major teaching hospital and research institution conducting clinical studies on neurological conditions.

The details

The project uses wearable digital sensors to track the 95th centile of stride velocity, a metric that captures a patient's natural walking speed outside of a clinic. Researchers are testing this data against clinical milestones and Global Rating of Change scores to determine if it accurately reflects disease progression. By validating these measurements, the study intends to provide the necessary evidence to support the inclusion of digital mobility metrics as secondary or exploratory endpoints in Phase II and III clinical trials.

October 30, 2026: Project announcement date.

Health Landscape

This project aligns with the FDA Digital Health Technologies Drug Development Demonstration Projects, which promote the use of digital tools in clinical research. It represents a broader effort to modernize how scientists track mobility in chronic, progressive conditions.

While this research is focused on clinical trials, it underscores the potential for digital mobility tools to better capture health status in real-world settings. Patients interested in how mobility tracking may influence future care or trial eligibility should speak with their neurologist.

The takeaway

Digital sensors could soon provide a more objective way to monitor physical performance in neurodegenerative disease trials. Discuss with your physician whether digital health tracking tools are appropriate for monitoring your own physical milestones.